Open Access

Meta-analysis confirms association between TNFA- G238A variant and JIA, and between PTPN22-C1858T variant and oligoarticular, RF-polyarticular and RF-positive polyarticular JIA

  • Merlyn J Kaalla1,
  • K Alaine Broadaway2,
  • Mina Rohani-Pichavant1,
  • Karen N Conneely2,
  • April Whiting3,
  • Lori Ponder4,
  • David T Okou1,
  • Sheila Angeles-Han1, 4,
  • Kelly Rouster-Stevens1, 4,
  • Milton R Brown1,
  • Larry B Vogler1, 4,
  • Lynn B Jorde5,
  • John F Bohnsack3,
  • Michael P Epstein2 and
  • Sampath Prahalad1, 2, 4Email author
Contributed equally
Pediatric Rheumatology201311:40

https://doi.org/10.1186/1546-0096-11-40

Received: 16 April 2013

Accepted: 18 August 2013

Published: 25 October 2013

Abstract

Background

Although more than 100 non-HLA variants have been tested for associations with juvenile idiopathic arthritis (JIA) in candidate gene studies, only a few have been replicated. We sought to replicate reported associations of single nucleotide polymorphisms (SNPs) in the PTPN22, TNFA and MIF genes in a well-characterized cohort of children with JIA.

Methods

We genotyped and analyzed 4 SNPs in 3 genes: PTPN22 C1858T (rs2476601), TNFA G-308A, G-238A (rs1800629, rs361525) and MIF G-173C (rs755622) in 647 JIA cases and 751 healthy controls. We tested for association between each variant and JIA as well as JIA subtypes. We adjusted for multiple testing using permutation procedures. We also performed a meta-analysis that combined our results with published results from JIA association studies.

Results

While the PTPN22 variant showed only modest association with JIA (OR = 1.29, p = 0.0309), it demonstrated a stronger association with the RF-positive polyarticular JIA subtype (OR = 2.12, p = 0.0041). The MIF variant was not associated with the JIA as a whole or with any subtype. The TNFA-238A variant was associated with JIA as a whole (OR 0.66, p = 0.0265), and demonstrated a stronger association with oligoarticular JIA (OR 0.33, p = 0.0006) that was significant after correction for multiple testing. TNFA-308A was not associated with JIA, but was nominally associated with systemic JIA (OR = 0.33, p = 0.0089) and enthesitis-related JIA (OR = 0.40, p = 0.0144). Meta-analyses confirmed significant associations between JIA and PTPN22 (OR 1.44, p <0.0001) and TNFA-238A (OR 0.69, p < 0.0086) variants. Subtype meta-analyses of the PTPN22 variant revealed associations between RF-positive, RF-negative, and oligoarticular JIA, that remained significant after multiple hypothesis correction (p < 0.0005, p = 0.0007, and p < 0.0005, respectively).

Conclusions

We have confirmed associations between JIA and PTPN22 and TNFA G-308A. By performing subtype analyses, we discovered a statistically-significant association between the TNFA-238A variant and oligoarticular JIA. Our meta-analyses confirm the associations between TNFA-238A and JIA, and show that PTPN22 C1858T is associated with JIA as well as with RF-positive, RF-negative and oligoarticular JIA.

Keywords

GeneticsJuvenile idiopathic arthritisAssociationReplication

Background

Juvenile idiopathic arthritis (JIA) refers to a collection of chronic autoimmune arthropathies in children. Although the etiology of JIA is complex, substantial evidence supports the importance of genetic factors in susceptibility to JIA [13]. While associations between JIA and variants in HLA are well established, non-HLA genetic variants also play a role in JIA susceptibility, and have increasingly been identified by genome-wide and candidate gene studies [46]. However, candidate-gene association studies of non-HLA variants in JIA have led to inconsistent results. Of nearly 100 non-HLA polymorphisms tested for associations with JIA by candidate gene studies, only a handful of associations have been replicated in independent cohorts [2, 5, 7, 8]. More recently, the International JIA Immunochip consortium has confirmed many of the genetic associations and also identified several new loci with genome-wide evidence for association [9].

In previous non-HLA genetic association studies, a functional variant at PTPN22 (C1858T) has been consistently associated with JIA [6, 1012]. Variants at MIF (G-173C) and TNFA (G-308A, G-238A) genes have also been associated with JIA, although some of the studies show mixed results [1321]. The reasons for non-replication are myriad, but chief among them is inadequate power due to small cohorts. One way to overcome this limitation is to perform meta-analyses of published studies. Meta-analyses have confirmed associations between JIA and genetic variants in STAT4, TNFAIP3, IL2RA, and CCR5, and have failed to find an association with CTLA4 variants [7, 22, 23]. Our objectives were to test previously associated variants at the TNFA and MIF loci in an independent JIA cohort and then to combine these results with published results in a meta-analysis. Furthermore, since prior studies of the PTPN22 variant have investigated combined JIA cohorts, we sought to investigate associations between JIA categories and the PTPN22 variant by meta-analysis.

Methods

Cases were 647 children with JIA from Pediatric Rheumatology clinics at the University of Utah (N = 437 cases, 750 controls) and Emory University (N = 210 cases). Patients were diagnosed according to the ILAR criteria [24]. The median age of onset was 5.8 years, and 67% of the cases were female. There were 50 children with systemic JIA, 48 with rheumatoid factor (RF)-positive polyarticular JIA, 159 with RF-negative polyarticular JIA, 58 with enthesitis-related arthritis (ERA), 287 with oligoarticular JIA, and 45 with other categories. Controls were 751 healthy adults (59% female) screened for several common autoimmune diseases and ascertained from the same geographic region as the Utah cases. Only subjects of self-reported Northern European ancestry were included in this study. A questionnaire was used to screen controls for autoimmune disorders. Controls who reported an autoimmune disorder were excluded. Subjects were enrolled under protocols approved by the Institutional Review Boards at the University of Utah and Emory University.

Genotyping

DNA was isolated from peripheral blood using the Puregene DNA purification kit from Qiagen (Valencia, CA). Subjects were genotyped for four SNPs in three loci: rs2476601 (C1858T) in the PTPN22 locus, rs1800629 (G-308A) and rs361525 (G-238A) in the TNFA locus and rs755622 (G-173C) in the MIF locus. These variants were chosen because of their reported associations with JIA in more than one cohort based on a review of published literature [2, 6, 1012, 14, 1618, 2531]. Genotyping of cases and controls was performed using Taqman pre-designed SNP genotyping assays (Applied Biosystems, Foster City, CA) according to the manufacturer’s protocols. To ensure quality control, ~3% of the samples were genotyped in duplicate to ensure accuracy and were found to be concordant. DNA samples with low genotyping success were removed from analyses.

Statistical analysis

Prior to association analysis, we first tested whether each variant was in Hardy-Weinberg equilibrium (HWE) in controls. We then tested for association between each variant and disease outcome using a logistic regression model assuming an additive model of allelic effect and adjusting for gender. From such models, we calculated allelic odds ratios (OR) and 95% confidence intervals (95% CI) that were adjusted for gender. Since these variants have been previously implicated in susceptibility to JIA and other autoimmune disorders, we considered JIA to be the primary disease phenotype. However, since JIA is a collection of several heterogeneous subtypes, we repeated the analyses for specific JIA subtypes based on ILAR criteria. Since each of these variants has been previously implicated as being associated with JIA, we initially focused on nominal significance (p < 0.05) but subsequently adjusted for multiple comparisons using a permutation procedure. Our permutation procedure generated 1000 datasets under the null hypothesis of no association between JIA and genotype by repeatedly shuffling the vector of genotypes for each subject in the dataset. This type of permutation procedure preserves both the linkage disequilibrium among variants and the known effects of gender on JIA. We carried out all analyses using the R programming language [32].

As we studied variants previously investigated for association with JIA, we performed a meta- analysis of these variants that combined our study with published case-control association studies of JIA (identified using a PUBMED search). Using allele frequency data derived from these studies, we performed meta-analyses of PTPN22, TNFA and MIF associations with JIA using a fixed-effects model that weighted studies by number of subjects. We established significance using Cochran-Mantel-Haenszel tests. We used Cochran’s Q test to assess heterogeneity among studies, with a significance level set at p < 0.10, as is recommended for Cochran’s Q test [33, 34]. When we identified heterogeneity between studies, we repeated the analyses after removing the study responsible for the heterogeneity. As an alternate analysis, we performed all the meta-analyses using an unconditional generalized linear mixed-effects model, which allowed for random study effects. We performed the meta- analyses using the R package “metafor” [35].

Results

We found that all four SNPs were in approximate HWE in our controls, using the Bonferroni-adjusted alpha threshold of 0.0125. In our cohort, we removed 1 of the 647 cases missing gender information. Furthermore, we found that 17 individuals were missing genotype data at MIF genotypes, 28 were missing PTPN22, 10 were missing TNFA238, and 40 were missing TNFA308 yielding genotyping success rates ranging between 97.2% to 99.3%.

Using logistic regression, we observed that the PTPN22 1858 T variant showed a nominal association in our JIA cohort (OR = 1.29, p = 0.0309) (Table 1). After stratification by subtype, we observed the variant was nominally associated with two subgroups: those with RF- positive polyarticular JIA (OR 2.12; p = 0.0041) and oligoarticular JIA (OR = 1.35, p = 0.0400) (Table 2).
Table 1

Case-control analysis of PTPN22, TNFA and MIF variants and JIA

 

Cases

Controls

  

Variant

# Cases

MAF

# Controls

MAF

OR (95% CI)

p-value

PTPN22 C1858T

636

0.13

733

0.11

1.29 (1.02-1.62)

0.0309

MIFG-173C

638

0.18

742

0.17

1.06 (0.88-1.29)

0.5353

TNFA G-238A

638

0.04

749

0.06

0.66 (0.46, 0.95)

0.0265

TNFA G-308A

628

0.14

729

0.17

0.82 (0.66, 1.01)

0.0574

Table 2

Results of case-control association of PTPN22, MIF and TNFA variants among JIA sub-phenotypes

 

PTPN22

MIF

TNFA G-238A

TNFA G-308A

Subtype

# Cases

OR (95% CI)

# Cases

OR (95% CI)

# Cases

OR (95% CI)

# Cases

OR (95% CI)

Systemic

50

1.06 (0.53, 1.91)

49

1.53 (0.93, 2.45)

50

1.69 (0.76, 3.36)

50

0.33 (0.13, 0.69) 4

RF-Positive

48

2.12 (1.24, 3.49) 1

47

1.06 (0.60, 1.75)

48

*

47

0.98 (0.54, 1.66)

RF-Negative

154

1.09 (0.74, 1.57)

158

0.86 (0.61, 1.19)

157

1.14 (0.67, 1.86)

156

0.85 (0.60, 1.18)

ERA

55

1.09 (0.55, 1.97)

56

1.23 (0.74, 1.98)

56

0.94 (0.35, 2.06)

56

0.40 (0.18, 0.78) 5

Oligoarticular

284

1.35 (1.01, 1.80) 2

283

1.06 (0.83, 1.36)

284

0.33 (0.16, 0.59) 3

276

0.96 (0.73, 1.25)

1 p = 0.0041; 2 p = 0.0400; 3 p = 0.0006; 4 p = 0.0089; 5 p = 0.0144; Statistically significant results are bolded. * Represents an analysis that was not conducted due to small cell size.

The PTPN22 variant has been investigated for an association with JIA in seven other case-control comparisons (Table 3) [6, 8, 1012, 25, 26]. (Some of our subjects were included in a replication study of several autoimmunity associated variants in JIA [6]. In order to avoid duplication, the replication cohort used in the study by Thompson et al. was not included in our meta-analysis). Subjects in the studies included in our meta-analysis were of European ancestry. The pooled meta-analysis confirmed a strong association between JIA and PTPN22 with an OR of 1.44 (95% CI [1.31, 1.60]), p < 0.0001 (Figure 1, Table 4). When all seven studies plus our data were included, Cochran’s Q test for heterogeneity was not significant at the p = 0.10 threshold (p = 0.11).
Table 3

Studies included in meta-analyses

     

Cases

Controls

Gene

Author

Ref number

Country

Publication year

# Cases

MAF

# Controls

MAF

PTPN22 C1858T

Seldin et al.

[7]

Finland

2005

230

0.18

1400

0.15

Hinks et al.

[5]

UK

2005

661

0.15

595

0.10

Cinek et al.

[18]

Czech/Azeri

2007

130

0.21

400

0.10

Pazar et al.

[19]

Hungary

2008

150

0.09

200

0.08

Thompson et al.

[4]

USA

2010

809

0.14

531

0.09

Ellis

[29]

Australian

2013

324

0.10

568

0.07

Viken et al.

[6]

Norway

2005

320

0.16

555

0.12

Kaalla et al.

Present

USA

 

637

0.13

733

0.11

MIF G-173C

Donn et al.*

[[16]]

UK

2002

526

0.19

259

0.11

Miterski et al.

[9]

Germany

2004

150

0.24

390

0.21

Berdeli et al.

[13]

Turkey

2006

67

0.13

153

0.10

Kaalla et al.

Present

USA

 

639

0.18

742

0.17

TNFA G-238A

Ozen et al.*

[[22]]

Turkey

2002

51

0.22

93

0.27

Ozen et al.*

[[22]]

Czech

2002

159

0.23

100

0.17

Zeggini et al.

[23]

UK

2002

137

0.03

76

0.09

Miterski et al.

[9]

Germany

2004

130

0.02

375

0.03

Modesto et al.

[20]

Spain

2005

55

0.07

59

0.09

Schmeling et al.

[11]

Germany

2006

228

0.03

196

0.03

Kaalla et al.

Present

USA

 

639

0.04

749

0.06

TNFA G-308A

Ozen et al.*

[22]

Turkey

2002

51

0.25

93

0.31

Ozen et al.*

[22]

Czech

2002

159

0.27

100

0.16

Zeggini et al.

[23]

UK

2002

138

0.24

75

0.13

Miterski et al.

[9]

Germany

2004

122

0.17

312

0.16

Modesto et al.

[20]

Spain

2005

55

0.13

59

0.12

Schubert et al.

[12]

Germany

2006

86

0.15

270

0.15

Schmeling et al.

[11]

Germany

2006

228

0.14

196

0.17

Mourao et al.

[21]

Portugal

2009

115

0.12

118

0.11

Kaalla et al.

Present

USA

 

629

0.14

729

0.17

*Bolded studies were removed from analysis due to evidence for heterogeneity, using Cochran’s Q test (p < 0.10 threshold).

Figure 1

Forest Plots of meta-analyses, including all studies.

Table 4

Meta-analysis results for PTPN22, MIF and TNFA variants and JIA

  

Cases

Controls

   

Gene

 

# Cases

MAF

# Controls

MAF

OR (95% CI)

p-value

Data sources

PTPN22 C1858T

All Studies

3261

0.14

4982

0.11

1.44 (1.31, 1.60)

<0.0001

4-7, 18,19, 29

MIF G-173C

Including Donn et al. [16]

1382

0.19

1544

0.17

1.26 (1.09, 1.45)

0.0356

9, 13, 16

Removing Donn et al.

856

0.19

1285

0.18

1.12 (0.96, 1.32)

0.1548

 

TNFA G-238A

Including Ozen et al. [22]

1399

0.07

1648

0.07

0.84 (0.68, 1.04)

0.1033

9, 11, 20, 22, 23

Removing Ozen et al.

1189

0.03

1455

0.04

0.69 (0.52, 0.91)

0.0086

 

TNFA G-308A

Including Ozen et al. [22]

1583

0.17

1952

0.16

1.01 (0.88, 1.15)

0.925

9, 11, 12, 20-23

Removing Ozen et al.

1373

0.15

1759

0.16

0.95 (0.83, 1.10)

0.5137

 
Of the seven studies, only Hinks et al. study reported data by subtype [10]. We performed a pooled subtype meta-analysis using our data and data from Hinks et al. The meta-analysis confirmed findings from our cohort: the variant was significantly associated with RF-positive, RF-negative, and oligoarticular JIA (p < 0.0005, p = 0.0007 and p < 0.0005, respectively) (Table 5). Findings remained significant after correction for multiple hypothesis testing. Systemic JIA and ERA were not significantly associated with PTPN22.
Table 5

Meta-Analysis results for PTPN22 C1858T subtypes: combining Hinks et al. [[5]] data with data from our cohort

 

Hinks et al. [[5]]

Kaalla et al. (Present)

Combined

Category

Size

MAF

OR (95% CI)

Size

MAF

OR (95% CI)

OR (95% CI)

p-value

Systemic

118

0.09

0.89 (0.55, 1.44)

50

0.11

1.05 (0.55, 2.01)

0.94 (0.64, 1.39)

0.7675

RF-Positive

35

0.17

1.79 (0.94, 3.43)

48

0.21

2.24 (1.33, 3.77)

2.05 (1.37, 3.77)

<0.0005

RF-Negative

135

0.2

2.12 (1.49, 3.02)

154

0.12

1.13 (0.77, 1.66)

1.56 (1.21, 2.02)

0.0007

ERA

48

0.14

1.36 (0.74, 2.51)

55

0.11

1.04 (0.56, 1.94)

1.19 (0.77, 1.84)

0.4431

Oligoarticular

276

0.15

1.56 (1.16, 2.10)

284

0.14

1.36 (1.01, 1.82)

1.45 (1.18, 1.79)

<0.0005

Controls

595

0.1

NA

733

0.11

NA

NA

NA

PTPN22 allele frequency and odds ratios from Hinks et al. [5] and Kaalla et al. (Present) divided by five JIA categories. No covariates were included in the analyses. Pooled data significant at the α = 0.05 threshold level is bolded.

We observed no association between the MIF variant in our JIA cohort as a whole (OR 1.06, 95% CI [0.88-1.29], nor after stratification by subtype (Tables 1 and 2). The MIF variant has been investigated for an association with JIA in three other case-control comparisons, all of which examined European populations (Table 3) [14, 18, 31]. The meta-analysis of the three previous studies and our data demonstrated (Figure 1) an association between JIA and MIF G-173C (OR 1.26, 95% CI [1.09, 1.45]; p = 0.0014). Cochran’s test for heterogeneity was significant (p = 0.04), however, because the Donn et al. study including subjects from the United Kingdom [21] demonstrated a much stronger association between MIF and JIA than the other studies (Table 3). After removing the study by Donn et al. from the analysis, we found the resulting association between MIF and JIA to be negligible (OR 1.12, 95% CI [0.96, 1.32], p = 0.15) (Table 4), suggesting that the initial association was driven by the Donn et al. study. Since the Hinks et al. [10] and Zeggini et al. [30] studies represent work from the same Manchester group, we were concerned that these studies may also lead to heterogeneity in our meta-analyses. Therefore, we tested for effect of the PTPN22 and the TNFA variants, and excluded the Hinks and Zeggini results. Although the magnitude of the odds ratios for the three tests decreased with the reduced sample, inference for all three associations did not change. Additionally, we were concerned that removing apparently heterogeneous studies was too conservative an approach; therefore, we re-ran meta-analyses using a generalized linear mixed-effects model with random study effects. Results of the mixed-effects models can be seen in the Additional file 1: Table S1. Results were comparable to the fixed-effects models in which all studies were included in analysis.

TNFA-238A was associated with JIA in our cohort (OR 0.66, p = 0.0265) (Table 1). Upon stratifying the analysis by JIA subtype, we observed the most pronounced association between TNFA-238A and oligoarticular JIA (OR 0.33, p = 0.0006); no other subtypes were significantly associated with this SNP (Table 2). The association between oligoarticular JIA and TNFA-238A was the strongest association found in this study and remained significant after adjusting for multiple hypothesis testing using permutation resampling (corrected p = 0.0113). While the TNFA-308A showed no association with the entire JIA cohort, there was a nominal association between this SNP and systemic JIA (OR 0.33, p = 0.0089) and ERA (OR 0.40, p = 0.0144) (Tables 1 and 2).

Five studies have previously investigated the TNFAG-238A variant [14, 16, 27, 29, 30] and seven have investigated the TNFAG-308A variant [14, 16, 17, 2730] (Table 3). One of the studies, by Ozen et al. [29], investigated both TNFA variants in Turkish and Czech cases and controls; the others studied Western European populations [29]. The minor allele frequencies (MAF) reported in Ozen et al. differed widely from the other studies: MAF for TNFAG-238A in Ozen et al.’s sample was 0.27 (vs. 0.03 for other studies) and MAF was 0.31 (vs. 0.11) for TNFA G-308A (Table 3). Including data from Ozen et al. in the meta-analysis (Figure 1) resulted in significant evidence for heterogeneity (p = 0.05 and p = 0.004 for TNFAG-238A and TNFAG-308A, respectively), and hence the meta-analyses were repeated after excluding the study (Table 4) and by using a random effects model (Additional file 1: Table S1). There was a lack of association between JIA and either TNFA variant when we included all studies; however, after excluding the Ozen et al. study, we identified an association between TNFA-238A and JIA (OR 0.69, 95% CI [0.52, 0.91], p = 0.0086) (Table 4). We observed no association between TNFA-308A and JIA (Table 4, Figure 1).

Discussion

JIA is a complex trait believed to be influenced by both genetic and environmental factors [1]. Convincing associations between polymorphisms in the genes encoding the human leukocyte antigens (HLA) and JIA have been reported in multiple cohorts. HLA-DR is estimated to account for only ~17% of susceptibility to JIA, suggesting that non-HLA loci contribute substantially to JIA susceptibility [36]. To date, a few non-HLA variants have been demonstrated to have replicable associations. A comprehensive review of non-HLA associations suggested that most studies are underpowered and very few positive associations are replicated [2]. A handful of genes, including PTPN22, TNFAIP3, STAT4, PTPN2, and CCR5, have shown replicated associations [5, 6, 22, 37], but many other associations have not been formally replicated. One strategy to improve power and develop a more accurate estimate of effect size in genetic associations is to perform meta-analysis of published studies to validate previous associations, as we did in this study. Our meta-analysis, with 3200 cases with JIA and over 5000 controls confirms a statistically significant association between PTPN22 and JIA.

The gene TNFA, which encodes the proinflammatory cytokine TNF-α, is located in the MHC region on chromosome 6 and has been implicated in susceptibility to a number of rheumatic diseases, including rheumatoid arthritis. TNFA variants have been investigated for an association with JIA in a variety of studies. While associations between microsatellite polymorphisms in TNFA and different subtypes of JIA have been reported in various studies [1315], investigations of two functional SNPs have yielded mixed results. We were able to find an association between the G-238A variant and oligoarticular JIA. The meta-analysis also suggests an association. Since the TNFA locus is in the MHC region, the associations observed could reflect linkage disequilibrium with HLA variants.

Our combined JIA cohort, while larger than several previously published cohorts, was still underpowered to detect small effects. For our primary analyses, we analyzed the JIA cohort as a whole, given the recent demonstration that clinically distinct autoimmune disorders share common susceptibility loci [3840]. Since JIA is a collection of heterogeneous subtypes, we also performed stratified analyses of JIA sub-phenotypes in our data, but our power to detect associations with some of the less common JIA categories was low. Only one other study, Hinks et al., provided genotype data by category [10]. In a pooled analysis with their data, the importance of analysis by categories was emphasized; the strongest associations we found were in JIA subphenotypes, rather than the global JIA phenotype. Analyzing by subphenotype therefore appears to be a valuable procedure, as it reduces the negative impact of phenotypic and genetic heterogeneity.

A limitation with all candidate gene studies is the potential of population stratification. While we attempted to minimize the effects of stratification by selecting only self-reporting European ancestry for our cohort and including only studies from Northern European samples in our meta-analysis, we acknowledge that this effect could perhaps influence our findings. We were also concerned about site heterogeneity in our study, since controls were obtained from Utah, while cases were obtained from both Utah and Georgia. Therefore, we re-ran our analyses with only Utah cases (N = 432) and controls (N = 750). Although the standard deviation increased with decreasing sample sizes, point estimates remained approximately identical for all analyses, indicating that between -site heterogeneity does not to appear to be a concern in our study. Results of these analyses can be seen in Additional file 2: Table S2 and Additional file 3: Table S3.

Other meta-analyses between JIA and these variants have been published recently [41, 42]. Lee et al. found no association between JIA and TNFA G-238A and TNFA G-308A variants among European subjects [41]. In contrast, our results do support an association between TNFA G-238A and JIA, and in particular oligoarticular JIA (significant after correction for multiple testing). Our meta-analysis also supported an association between this variant and JIA. As previously reported by Lee et al., we also did not find an association between JIA and TNFA G-308A[41]. Based on their meta-analysis, Lee et al. concluded there was association between PTPN22 C1858T and MIF C-173G variants [42]. While we confirmed the association between PTPN22 C1858T and JIA, we did not confirm the association with the MIF C-173G variant. There are several possible explanations for the discrepancies observed. First there might be true differences between the different populations being evaluated. Second, by the addition of almost 1400 subjects, our meta-analysis benefited from improved power. Third, the studies included in the meta-analyses varied somewhat. For instance, Lee et al. chose to include a study by Hohler et al., which investigated an association between TNFA G-238A and juvenile psoriatic arthritis and psoriasis [43]. We did not include the study by Hohler et al in our meta-analysis, since the subjects in their study were all adults, with “juvenile onset” having been defined as onset before the age of 40. In addition other subjects in that study had psoriasis without arthritis. Thus we felt their inclusion of these subjects in a meta-analysis of JIA was inappropriate. Finally, it should be noted that the minor allele frequencies extracted by Lee et al. for PTPN22 C1858T from the study by Thompson et al [6]. were substantially different than the actual frequencies reported in the original paper. Whereas Thompson et al. reported the case/control MAF for PTPN22 C1858T to be 0.143/0.094 and 0.149/0.095 for the initial and replication cohorts respectively (Tables 2 and 3 in Thompson et al. [6]), Lee et al. report these to be 0.249/0.193 and 0.252/0.204 for the same cohorts (Table 1, Lee et al. [42]).

Conclusions

In conclusion, our study provides convincing, replicated evidence that PTPN22 is associated with JIA. Our study also demonstrates the increased power of meta-analysis, and demonstrates that the PTPN22 C1858T variant is particularly associated with RF-negative, RF-positive and oligoarticular JIA categories, but not with ERA or systemic JIA. PTPN22 C1858T variant has been identified as an underlying risk factor for several different autoimmune phenotypes [38, 44, 45]. Our finding supports the notion that clinically distinct autoimmune phenotypes can share common susceptibility factors, offering a potential target for further research and possible therapy. Our study also demonstrates an association between oligoarticular JIA and TNFA-238A, supporting future investigations of the TNF-α pathway in JIA.

Notes

Declarations

Acknowledgements

Supported by The National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23-AR50177, R01-AR060893), and The National Center for Research Resources (UL1-RR025764 and C06-RR11234), The Arthritis Foundation, and The Val A Browning Charitable Foundation, and The Primary Children’s Medical Center Foundation, Salt Lake City, UT, and the Marcus Foundation Inc., Atlanta, GA. We are grateful to Dr. Stephen Guthery MD, at the University of Utah for sharing control samples and Bronte Clifford for subject enrollment.

Authors’ Affiliations

(1)
Departments of Pediatrics, Emory University School of Medicine
(2)
Department of Human Genetics, Emory University School of Medicine
(3)
Department of Pediatrics, University of Utah School of Medicine
(4)
Children’s Healthcare of Atlanta
(5)
Eccles Institute of Human Genetics, University of Utah

References

  1. Glass DN, Giannini EH: Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum. 1999, 42 (11): 2261-2268. 10.1002/1529-0131(199911)42:11<2261::AID-ANR1>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
  2. Prahalad S, Glass DN: A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2008, 6 (1): 11-10.1186/1546-0096-6-11.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Prahalad S, Zeft AS, Pimentel R, Clifford B, McNally B, Mineau GP: Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum. 2010, 62 (8): 2525-2529. 10.1002/art.27516. Epub 2010/05/28PubMed CentralView ArticlePubMedGoogle Scholar
  4. Hinks A, Eyre S, Ke X, Barton A, Martin P, Flynn E: Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis. Genes Immun. 2010, Epub 2010/01/15Google Scholar
  5. Hinks A, Eyre S, Ke X, Barton A, Martin P, Flynn E: Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis. 2010, 69 (6): 1049-1053. 10.1136/ard.2009.110650. Epub 2009/08/14PubMed CentralView ArticlePubMedGoogle Scholar
  6. Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, Tsoras M: The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum. 2010, 62 (11): 3265-3276. 10.1002/art.27688. Epub 2010/08/20PubMed CentralView ArticlePubMedGoogle Scholar
  7. Angeles-Han S, Prahalad S: The genetics of juvenile idiopathic arthritis: what is new in 2010?. Curr Rheumatol Rep. 2010, 12 (2): 87-93. 10.1007/s11926-010-0087-0. Epub 2010/04/29View ArticlePubMedGoogle Scholar
  8. Ellis JA, Chavez RA, Pezic A, Ponsonby AL, Akikusa JD, Allen RC: Independent replication analysis of genetic loci with previous evidence of association with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2013, 11 (1): 12-10.1186/1546-0096-11-12. Epub 2013/03/20PubMed CentralView ArticlePubMedGoogle Scholar
  9. Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J: Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet. 2013, 45 (6): 664-669. 10.1038/ng.2614. Epub 2013/04/23PubMed CentralView ArticlePubMedGoogle Scholar
  10. Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE: Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 2005, 52 (6): 1694-1699. 10.1002/art.21049.View ArticlePubMedGoogle Scholar
  11. Viken MK, Amundsen SS, Kvien TK, Boberg KM, Gilboe IM, Lilleby V: Association analysis of the 1858C > T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes Immun. 2005, 6 (3): 271-273. 10.1038/sj.gene.6364178.View ArticlePubMedGoogle Scholar
  12. Seldin MF, Shigeta R, Laiho K, Li H, Saila H, Savolainen A: Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis. Genes Immun. 2005, 6 (8): 720-722.PubMedGoogle Scholar
  13. Epplen C, Rumpf H, Albert E, Haas P, Truckenbrodt H, Epplen JT: Immunoprinting excludes many potential susceptibility genes as predisposing to early onset pauciarticular juvenile chronic arthritis except HLA class II and TNF. Eur J Immunogenet. 1995, 22 (4): 311-322. 10.1111/j.1744-313X.1995.tb00247.x.View ArticlePubMedGoogle Scholar
  14. Miterski B, Drynda S, Boschow G, Klein W, Oppermann J, Kekow J: Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet. 2004, 5 (1): 2-PubMed CentralView ArticlePubMedGoogle Scholar
  15. Nikitina Zake L, Cimdina I, Rumba I, Dabadghao P, Sanjeevi CB: Major histocompatibility complex class I chain related (MIC) A gene, TNFa microsatellite alleles and TNFB alleles in juvenile idiopathic arthritis patients from Latvia. Hum Immunol. 2002, 63 (5): 418-423. 10.1016/S0198-8859(02)00385-3.View ArticlePubMedGoogle Scholar
  16. Schmeling H, Wagner U, Peterson A, Horneff G: Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2006, 24 (1): 103-108.PubMedGoogle Scholar
  17. Schubert K, von Bonnsdorf H, Burke M, Ahlert I, Braun S, Berner R: A comprehensive candidate gene study on bronchial asthma and juvenile idiopathic arthritis. Dis Markers. 2006, 22 (3): 127-132. 10.1155/2006/373620.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Berdeli A, Ozyurek AR, Ulger Z, Gurses D, Levent E, Salar K: Association of macrophage migration inhibitory factor gene -173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis. Rheumatol Int. 2006, 26 (8): 726-731. 10.1007/s00296-005-0062-7.View ArticlePubMedGoogle Scholar
  19. Berdeli A, Tabel Y, Celik HA, Ozyurek R, Dogrusoz B, Aydin HH: Lack of association between TNFalpha gene polymorphism at position -308 and risk of acute rheumatic fever in Turkish patients. Scand J Rheumatol. 2006, 35 (1): 44-47. 10.1080/03009740510026760.View ArticlePubMedGoogle Scholar
  20. De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R: Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003, 48 (5): 1398-1407. 10.1002/art.10882.View ArticlePubMedGoogle Scholar
  21. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M: Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002, 46 (9): 2402-2409. 10.1002/art.10492.View ArticlePubMedGoogle Scholar
  22. Hinks A, Martin P, Flynn E, Eyre S, Packham J, Barton A: Association of the CCR5 gene with juvenile idiopathic arthritis. Genes Immun. 2010, 11 (7): 584-589. 10.1038/gene.2010.25. Epub 2010/05/14PubMed CentralView ArticlePubMedGoogle Scholar
  23. Prahalad S, Honeggar M, Thompson SD, Glass DN, Bohnsack JF, Bamshad M: Lack of association of CTLA4 polymorphisms with juvenile rheumatoid arthritis. Arthritis Rheum. 2005, 52 (Suppl. 9): S302-Google Scholar
  24. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004, 31 (2): 390-392.PubMedGoogle Scholar
  25. Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, Kulich M: No independent role of the -1123 G > C and + 2740 A > G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res Clin Pract. 2007, 76 (2): 297-303. 10.1016/j.diabres.2006.09.009.View ArticlePubMedGoogle Scholar
  26. Pazar B, Gergely P, Nagy ZB, Gombos T, Pozsonyi E, Rajczy K: Role of HLA-DRB1 and PTPN22 genes in susceptibility to juvenile idiopathic arthritis in Hungarian patients. Clin Exp Rheumatol. 2008, 26 (6): 1146-1152. Epub 2009/02/13PubMedGoogle Scholar
  27. Modesto C, Patino-Garcia A, Sotillo-Pineiro E, Merino J, Garcia-Consuegra J, Merino R: TNF-alpha promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis. Scand J Rheumatol. 2005, 34 (6): 451-454. 10.1080/03009740510026652.View ArticlePubMedGoogle Scholar
  28. Mourao AF, Caetano-Lopes J, Costa P, Canhao H, Santos MJ, Pinto P: Tumor necrosis factor-alpha -308 genotypes influence inflammatory activity and TNF-alpha serum concentrations in children with juvenile idiopathic arthritis. J Rheumatol. 2009, 36 (4): 837-842. Epub 2009/02/12PubMedGoogle Scholar
  29. Ozen S, Alikasifoglu M, Bakkaloglu A, Duzova A, Jarosova K, Nemcova D: Tumour necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis. Rheumatology (Oxford). 2002, 41 (2): 223-227. 10.1093/rheumatology/41.2.223.View ArticleGoogle Scholar
  30. Zeggini E, Thomson W, Kwiatkowski D, Richardson A, Ollier W, Donn R: Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis Rheum. 2002, 46 (12): 3304-3311. 10.1002/art.10698.View ArticlePubMedGoogle Scholar
  31. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M: A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum. 2004, 50 (5): 1604-1610. 10.1002/art.20178.View ArticlePubMedGoogle Scholar
  32. R Core Team: R: A language and environment for statistical computing. 2012, Vienna, Austria: R Foundation for Statistical Computing,http://www.R-project.org/, 3-900051-07-0,Google Scholar
  33. Cochran W: The combination of estimates from different experiments. Biometrics. 1954, 10: 101-129. 10.2307/3001666.View ArticleGoogle Scholar
  34. Dickersin K, Berlin JA: Meta-analysis: state-of-the-science. Epidemiol Rev. 1992, 14: 154-176. Epub 1992/01/01PubMedGoogle Scholar
  35. Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stast Soft. 2010, 36: 1-48.Google Scholar
  36. Prahalad S, Ryan MH, Shear ES, Thompson SD, Giannini EH, Glass DN: Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in affected sibpairs. Arthritis Rheum. 2000, 43 (10): 2335-2338. 10.1002/1529-0131(200010)43:10<2335::AID-ANR22>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
  37. Prahalad S, Hansen S, Whiting A, Guthery SL, Clifford B, McNally B: Variants in TNFAIP3, STAT4, and C12orf30 loci associated with multiple autoimmune diseases are also associated with juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60 (7): 2124-2130. 10.1002/art.24618. Epub 2009/07/01PubMed CentralView ArticlePubMedGoogle Scholar
  38. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004, 75 (2): 330-337. 10.1086/422827.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004, 36 (4): 337-338. 10.1038/ng1323.View ArticlePubMedGoogle Scholar
  40. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW: STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007, 357 (10): 977-986. 10.1056/NEJMoa073003.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Lee YH, Bae SC, Song GG: TNF promoter -308 A/G and -238 A/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis. Mol Biol Rep. 2012, 39 (8): 8497-8503. 10.1007/s11033-012-1704-y. Epub 2012/06/15View ArticlePubMedGoogle Scholar
  42. Lee YH, Bae SC, Song GG: The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis. Inflamm Res. 2012, 61 (5): 411-415. 10.1007/s00011-012-0447-5. Epub 2012/02/14View ArticlePubMedGoogle Scholar
  43. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C: A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Investig Dermatol. 1997, 109 (4): 562-565. 10.1111/1523-1747.ep12337469. Epub 1997/10/27View ArticlePubMedGoogle Scholar
  44. Bottini N, Vang T, Cucca F, Mustelin T: Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol. 2006, 18 (4): 207-213. 10.1016/j.smim.2006.03.008.View ArticlePubMedGoogle Scholar
  45. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK: The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. Rheumatology (Oxford). 2006, 46 (1): 49-56.View ArticleGoogle Scholar

Copyright

© Kaalla et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement